Farydak (panobinostat) / Secura Bio  >>  Phase 3
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Farydak (panobinostat) / Secura Bio
PATH, NCT01034163 / 2009-014846-26: A Phase III Randomized, Double Blind, Placebo Controlled Multi-center Study of Panobinostat for Maintenance of Response in Patients With Hodgkin's Lymphoma (HL)

Completed
3
41
US, Canada, Europe, RoW
Panobinostat, LBH589, Placebo
Novartis Pharmaceuticals
Hodgkin's Lymphoma
05/12
05/12
PANORAMA-1, NCT01023308 / 2009-015507-52: Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma

Checkmark EHA 2016: PANORAMA-1
May 2016 - May 2016: EHA 2016: PANORAMA-1
Checkmark ASCO 2016
May 2016 - May 2016: ASCO 2016
Checkmark ASH 2015
More
Completed
3
767
Europe, Canada, Japan, US, RoW
Panobinostat, LBH589, Bortezomib, (Velcade®), Dexamethasone, Placebo
Novartis Pharmaceuticals
Multiple Myeloma
07/15
07/15
2017-000764-15: European Intergroup Trial on panobinostat maintenance after HSCT for high-risk AML and MDS - A randomized, multicenter phase III study to assess the efficacy of panobinostat maintenance therapy vs. standard of care following allogeneic stem cell transplantation in patients with high-risk AML or MDS

Ongoing
3
350
Europe
Farydak, Capsule, hard, Farydak
Universitätsklinikum Frankfurt, Novartis Pharma GmbH
High risk acute myeloid leukemia or myelodysplastic syndrome Hoch-risiko akute myeloische Leukämie oder myelodysplastisches Syndrom, Acute myeloid leukemia (AML). Myelodysplastic syndrome (MDS) Akute myeloische Leukämie (AML). Myelodysplastisches Syndrom (MDS)., Diseases [C] - Cancer [C04]
 
 
NCT04326764: Panobinostat Maintenance After HSCT fo High-risk AML and MDS

Terminated
3
52
Europe
Panobinostat, Farydak
Goethe University, Stichting Hemato-Oncologie voor Volwassenen Nederland, Polish Adult Leukemia Group, Schweizerische Arbeitsgemeinschaft für klinische Krebsforschung
Acute Myeloid Leukaemia (AML), Myelodysplastic Syndromes (MDS)
02/23
02/23

Download Options